Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Comparative Effectiveness of Warfarin and Newer Oral Anticoagulants for the Long-Term Prevention and Treatment of Arterial and Venous Thromboembolism [Internet].

Adam SS, McDuffie JR, Ortel TL, Nagi A, Williams JW Jr.

Washington (DC): Department of Veterans Affairs (US); 2012 Apr.

2.
3.

Treating patients with venous thromboembolism: initial strategies and long-term secondary prevention.

Huisman MV, Bounameaux H.

Semin Vasc Med. 2005 Aug;5(3):276-84.

PMID:
16123915
5.

Prevention of stroke in patients with atrial fibrillation.

Olsson SB, Halperin JL.

Semin Vasc Med. 2005 Aug;5(3):285-92. Review.

PMID:
16123916
6.

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation.

Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, Wang PJ, Turakhia MP.

Ann Intern Med. 2011 Jan 4;154(1):1-11. doi: 10.7326/0003-4819-154-1-201101040-00289. Epub 2010 Nov 1.

PMID:
21041570
7.
8.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
9.

Evaluation and management of atrial fibrillation.

Ali S, Hong M, Antezano ES, Mangat I.

Cardiovasc Hematol Disord Drug Targets. 2006 Dec;6(4):233-44. Review.

PMID:
17378769
10.

Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting.

Han SY, Palmeri ST, Broderick SH, Hasselblad V, Rendall D, Stevens S, Tenaglia A, Velazquez E, Whellan D, Wagner G, Heitner JF.

J Electrocardiol. 2013 Jan-Feb;46(1):45-50. doi: 10.1016/j.jelectrocard.2012.08.011. Epub 2012 Oct 11.

PMID:
23063241
11.

New oral anticoagulants for atrial fibrillation: a review of clinical trials.

O'Dell KM, Igawa D, Hsin J.

Clin Ther. 2012 Apr;34(4):894-901. doi: 10.1016/j.clinthera.2012.01.019. Epub 2012 Mar 13. Review.

PMID:
22417716
12.

Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink.

Macedo AF, Bell J, McCarron C, Conroy R, Richardson J, Scowcroft A, Sunderland T, Rotheram N.

Thromb Res. 2015 Aug;136(2):250-60. doi: 10.1016/j.thromres.2015.06.007. Epub 2015 Jun 9.

13.
14.

Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.

Lane DA, Raichand S, Moore D, Connock M, Fry-Smith A, Fitzmaurice DA; Steering Committee.

Health Technol Assess. 2013 Jul;17(30):1-188. doi: 10.3310/hta17300. Review.

15.

Venous thromboembolism in cancer patients.

Deng A, Galanis T, Graham MG.

Hosp Pract (1995). 2014 Dec;42(5):24-33. doi: 10.3810/hp.2014.12.1156. Review.

PMID:
25485915
16.
17.

Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.

Salim I, Al Suwaidi J, Ghadban W, Salam AM.

Expert Opin Drug Saf. 2013 Jan;12(1):53-63. doi: 10.1517/14740338.2013.732569. Epub 2012 Oct 24. Review.

PMID:
23095103
18.

Edoxaban in venous thromboembolism and stroke prevention: an appraisal.

Proietti M, Lip GY.

Vasc Health Risk Manag. 2016 Feb 29;12:45-51. doi: 10.2147/VHRM.S81569. eCollection 2016. Review.

19.

Atrial fibrillation and stroke prevention with warfarin in the long-term care setting.

Gurwitz JH, Monette J, Rochon PA, Eckler MA, Avorn J.

Arch Intern Med. 1997 May 12;157(9):978-84.

PMID:
9140268
20.

[New oral anticoagulants for the prevention of thromboembolism in atrial fibrillation: from clinical evidence to appropriate use].

Colonna P.

G Ital Cardiol (Rome). 2012 Nov;13(11 Suppl 1):3S-10S. doi: 10.1714/1179.13061. Review. Italian.

PMID:
23160014

Supplemental Content

Support Center